More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$61.59B
EPS
1.77
P/E ratio
48.9
Price to sales
7.54
Dividend yield
--
Beta
0.846171
Previous close
$107.15
Today's open
$107
Day's range
$104.94 - $108
52 week range
$74.66 - $108
show more
CEO
Bernard J. Zovighian
Employees
16000
Headquarters
Irvine, CA
Exchange
New York Stock Exchange
Shares outstanding
575000000
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Edwards Lifesciences Q3 Earnings Call Highlights
Edwards Lifesciences NYSE: EW raised its 2026 sales and earnings guidance after third-quarter results exceeded management's expectations, with growth across its heart-valve businesses and regions.
MarketBeat • Nov 7, 2026

Edwards Q3 Earnings & Revenues Surpass Estimates, Stock Climbs
EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.
Zacks Investment Research • Nov 5, 2026

Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8% Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%3 Q3 EPS of $0.531; adjusted2 EPS of $0.801 which grew 19% versus prior year 2026 Outlook Increasing t.
Business Wire • Nov 4, 2026

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Benzinga • Nov 4, 2026

Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript
Edwards Lifesciences Corporation (EW) Discusses CLASP II TR and PROGRESS Trial Results in Tricuspid and TAVR Transcript
Seeking Alpha • Nov 3, 2026

Can Q3 Earnings Get Back On Track After Being Rattled By Big Tech's AI Prints?
Heavy AI capex hit free cash flows at Alphabet and Meta, while Microsoft and Amazon faced mounting concerns over compressed margins, search cannibalization, and agentic commerce disruption. With Apple reporting on an unusual Monday schedule, nine S&P 500 firms confirmed delayed reporting dates, a historical indicator of potential bad news ahead. This marks the second week of Q3 earnings season, with 2,465 companies expected to report and overall S&P 500 EPS growth holding at a robust 29.5%.
Seeking Alpha • Nov 3, 2026

Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits
Edwards Lifesciences NYSE: EW highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replacement programs, including results from the CLASP IITR trial of the PASCAL system and the PROGRESS trial evaluating TAVR in certain patients with moderate aortic stenosis. Get Edwards Lifesciences alerts:Sign UpCLASP IITR meets six-month primary endpoint Charlie Davidson, chief of cardiology and medical director of the Bluhm Cardiovascular Institute and global co-principal investigator of CLASP IITR, said the trial met its six-month composite primary endpoint.
MarketBeat • Nov 3, 2026

CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. The evidence further showed significant reduction of tricuspid regurgitation (TR) and substantially improved health status, both sustained through one year. The data were presented during late-breaking clinical trial sessions at Transcatheter Cardi.
Business Wire • Nov 2, 2026

Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demonstrated that transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance in the primary composite endpoint of death or heart failure events at two years in moderate AS patients with at-risk features. The late-breaking results were presented at Transcatheter Cardiovascular Th.
Business Wire • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Edwards Lifesciences Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.